Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
D4Z4 binding element transcript (DBE-T) is a long non-coding RNA expressed from the D4Z4 subtelomeric repeats on chromosome 4, particularly upregulated in facioscapulohumeral muscular dystrophy (FSHD) myoblasts[1][2][3]. DBE-T works as a chromatin-associated RNA that recruits the histone methyltransferase Ash1L to D4Z4 repeats, leading to a change in chromatin state and the derepression of nearby genes, including the disease-causing DUX4 gene[1]. This lncRNA thereby functions as an epigenetic regulator, linking chromatin architecture to the transcriptional activator events central to FSHD pathology. DBE-T itself does not encode a protein and is not a direct therapeutic target, but plays a key role in the molecular mechanisms driving FSHD[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D4Z4 binding element transcript (DBE-T).